Evidence map›Paper›PMID 42455269›Full record

ArticleInfection2026

Aminoglycosides: Is there an effective alternative in severe tularaemia? A case series.

Markus Fiedler, Matthias J Neuböck, Johannes Eimer, Gregor Ablinger, Georg Murauer, Helmut J F Salzer, Thierry Rolling

Abstract read
PubMed Publisher
In one paragraph

Article in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Markus FiedlerDepartment of Internal Medicine 4 - Pneumology, Kepler University Hospital, Linz, Austria.
Matthias J NeuböckMedical Faculty, Johannes Kepler University, Linz, Austria.
Johannes EimerMedical Faculty, Johannes Kepler University, Linz, Austria.
Gregor AblingerDepartment of Internal Medicine 4 - Pneumology, Kepler University Hospital, Linz, Austria.
Georg MurauerDepartment of Internal Medicine 4 - Pneumology, Kepler University Hospital, Linz, Austria.
Helmut J F SalzerMedical Faculty, Johannes Kepler University, Linz, Austria.
Thierry RollingMedical Faculty, Johannes Kepler University, Linz, Austria. Thierry.rolling@jku.at.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeSevere pulmonary tularaemia is rare, and evidence guiding optimal antimicrobial treatment remains limited. Although aminoglycosides are commonly recommended, their toxicity profile and practical limitations may complicate treatments. The purpose of this case series was to describe clinical outcomes in adult patients with severe pulmonary tularaemia caused by Francisella tularensis who were treated with fluoroquinolones or tetracyclines.;

methodsWe retrospectively describe six adult patients with severe pulmonary tularaemia. Clinical presentation, antimicrobial treatment, and clinical and radiological outcomes were reviewed, with a focus on response to targeted therapy with fluoroquinolones or tetracyclines.;

resultsAll six patients achieved complete clinical and radiological recovery following targeted antimicrobial therapy with either fluoroquinolones or tetracyclines despite severe pulmonary disease.;

conclusionThis case series provides consistent real-world evidence that fluoroquinolones and tetracyclines can achieve favourable outcomes in severe pulmonary tularaemia. These findings highlight their potential role as alternative treatment strategies and contribute meaningful data to the ongoing discussion on optimal antimicrobial management of tularaemia.

Indexed as

AminoglycosidesFluoroquinolonesPulmonary tularemiaTularemia

Identifiers

PMID42455269

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.